Capreomycin sulfate indications and usage

Revision as of 23:45, 25 December 2013 by Gerald Chi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Capreomycin Sulfate
CAPASTAT SULFATE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Indications and Usage

Capastat sulfate, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli.

Susceptibility studies should be performed to determine the presence of a capreomycin-susceptible strain of M. tuberculosis.[1]

References

  1. "CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN]". Text " accessdate " ignored (help)

Adapted from the FDA Package Insert.